Skip to main content
Back
TXG logo

10x Genomics, Inc.

Data quality: 100%
TXG
NASDAQ Healthcare Medical - Healthcare Information Services
$19.81
▲ $0.67 (3.50%)
Mkt Cap: 2.53B
Day Range
$18.77 $19.90
52-Week Range
$6.78 $23.56
Volume
1,603,050
50D / 200D Avg
$20.09 / $15.36
Prev Close
$19.14

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -58.1 0.3
P/B 3.2 2.9
ROE % -5.8 3.7
Net Margin % -6.8 3.8
Rev Growth 5Y % 7.0 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$21.00 +6.0%
Low: $17.00 High: $25.00
Forward EPS
-$0.84
Est. Revenue
610 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 -$0.36
-$0.37 – -$0.35
840 M 4
FY2029 -$0.37
-$0.38 – -$0.36
780 M 4
FY2028 -$0.53
-$0.85 – -$0.07
710 M 11

Key Takeaways

Revenue grew 7.00% annually over 5 years — modest growth
Debt/Equity of 0.20 — conservative balance sheet
Generating 130.12M in free cash flow
PEG of 0.61 suggests growth is underpriced
Capital efficient — spends only 0.92% of revenue on capex

Growth

Revenue Growth (5Y)
7.00%
Revenue (1Y)5.25%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-5.78%
ROIC-8.72%
Net Margin-6.77%
Op. Margin-17.25%

Safety

Debt / Equity
0.20
Current Ratio4.46
Interest Coverage0.00

Valuation

P/E Ratio
-58.12
P/B Ratio3.18
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5.25% Revenue Growth (3Y) 1.93%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 7.00% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 642.82M Net Income (TTM) -43.54M
ROE -5.78% ROA -4.18%
Gross Margin 69.05% Operating Margin -17.25%
Net Margin -6.77% Free Cash Flow (TTM) 130.12M
ROIC -8.72% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.20 Current Ratio 4.46
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -58.12 P/B Ratio 3.18
P/S Ratio 3.94 PEG Ratio 0.61
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.53B Enterprise Value 2.21B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 642.82M 610.79M 618.73M 516.41M 490.49M
Net Income -43.54M -182.63M -255.10M -166.00M -58.22M
EPS (Diluted) -0.35 -1.52 -2.18 -1.46 -0.53
Gross Profit 443.88M 414.48M 409.31M 396.02M 416.40M
Operating Income -110.89M -194.56M -265.33M -167.94M -52.91M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.04B 918.64M 965.14M 1.03B 1.02B
Total Liabilities 245.04M 208.50M 224.10M 223.24M 201.26M
Shareholders' Equity 796.33M 710.13M 741.04M 805.74M 817.57M
Total Debt 157.74M 82.61M 95.37M 95.18M 81.98M
Cash & Equivalents 473.97M 344.07M 359.28M 219.75M 587.45M
Current Assets 684.45M 584.39M 596.02M 635.04M 747.59M
Current Liabilities 153.45M 117.63M 127.16M 130.96M 110.36M